Kelley Mack cause of death: What is glioma of the central nervous system? All on Chicago Med star's health issues
Mack graduated from Hinsdale Central High School in 2010 and went on to earn a bachelor's degree in cinematography from Chapman University's Dodge College of Film in 2014.
Her interest in performing began after receiving a mini video camera as a birthday gift, which led to appearances in commercials as a child actor. She later won an acting award from NYU's Tisch School of the Arts for her debut performance in The Elephant Garden, a film that earned the Student Visionary Award at the 2008 Tribeca Film Festival.
She was best known for her television roles, including Addy in Season 9 of The Walking Dead, Penelope Jacobs in Season 8 of Chicago Med, and appearances on FOX's 9-1-1. Her film credits include Alice in Broadcast Signal Intrusion, Wilda in Delicate Arch, and Ricky in the upcoming Universal.
Beyond acting, Kelly Mack was also a screenwriter, collaborating with her mother, Kristen Klebenow, on multiple feature-length scripts. Among their projects was On The Black, a 1950s-era college baseball story inspired by her maternal grandparents' time at Ohio University.
She is survived by her parents, Kristen and Lindsay Klebenow; sister Kathryn; brother Parker; and grandparents Lois and Larry Klebenow.
What is glioma of the central nervous system?
According to the Cleveland Clinic, a glioma 'is a tumor that forms when glial cells grow out of control. Normally, these cells support nerves and help your central nervous system work. Gliomas usually grow in the brain, but can also form in the spinal cord'.
'Gliomas are malignant (cancerous), but some can be very slow growing. They're primary brain tumors, meaning they originate in the brain tissue,' the website further states.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
Doctors Flag Dangerous Trend As Mounjaro, Wegovy Misuse Spikes Among Indians For Quick Weight Loss
Last Updated: Originally developed to treat type 2 diabetes and medical obesity, GLP-1 receptor agonists like tirzepatide and semaglutide are now being widely misused for cosmetic weight loss When a 45-year-old air hostess began suffering from frequent vomiting and extreme fatigue, the initial assumption was that her erratic work hours were to blame. But a deeper investigation at Fortis Hospital in Mumbai revealed the real reason—she had been self-injecting Tirzepatide, a powerful drug meant for diabetes and medically supervised weight loss, without follow-up or guidance from any doctor. She claimed that she had received a prescription during an overseas consultation for pre-diabetes and weight concerns, but she continued the medicine on her own upon returning to India. 'Although the medicine was prescribed to her by an overseas doctor, she was not in touch with them. She didn't realise her side effects were linked to the drug," said Dr Shobha Manish Itolikar, consultant, internal medicine, Fortis Hospital Mulund. Eventually, side effects, including gastrointestinal distress and functional impairment set in—symptoms she didn't realise were linked to the drug. 'These are just some of the perils of the ongoing over-the-counter usage of newer drugs without proper surveillance by a doctor." This is not an isolated case. In fact, this case is part of a rapidly growing concern among Indian physicians. Originally developed to treat type 2 diabetes and medical obesity, GLP-1 receptor agonists like tirzepatide (marketed as Eli Lilly's Mounjaro) and semaglutide (marketed as Novo Nordisk's Wegovy and Ozempic) are now being widely misused for cosmetic weight loss. The Danish drugmaker's Wegovy was launched in India in July, and the American drugmaker's Mounjaro was launched in March. Dr Mayank Madan, director of gastrointestinal, minimal access, and bariatric surgery at CK Birla Hospital, Gurugram, said he sees 40-50 new such cases every month. 'As a bariatric and gastrointestinal surgeon, I am increasingly seeing more and more patients self-medicate with medications like Wegovy or Mounjaro for rapid weight loss—most often without proper medical monitoring. While they can be wonderfully effective if prescribed and monitored properly, unmonitored utilisation may lead to life-changing gastrointestinal and metabolic issues." The side effects range from chronic vomiting, acid reflux, severe constipation or diarrhoea, to nutritional deficiencies, gallstones, and even rare cases of pancreatitis. Some patients report prolonged weakness and muscle loss due to unintentional undernourishment. Novo Nordisk's Ozempic, the breakthrough weight loss drug which was originally approved only for diabetes, has a known history of off-label misuse globally as a 'slimming shot". Social media platforms are rife with posts glamorising these injectables as quick fixes for weight loss, even among non-diabetic individuals. This phenomenon, doctors say, has now trickled into India, where access to the drugs—either through overseas prescriptions, online purchases, or informal channels—has become dangerously easy. Dr Mohit Sharma, senior consultant, internal medicine and endocrinologist at Amrita Hospital, Faridabad, told News18, many patients now arrive at clinics after trying weight-loss diabetes drugs on their own. 'We are seeing more and more people coming to us after trying weight-loss diabetes drugs like Mounjaro and Wegovy on their own, without a doctor's advice. Many of them come in complaining of severe nausea, vomiting, stomach cramps, and feeling extremely weak or dehydrated." He explained that these medicines are very powerful and meant to be started in small doses, gradually increased under medical supervision. But people who self-prescribe often start with the wrong dose or don't know how to handle side effects. 'One big danger is that these medicines are not safe for everyone. If someone has hidden thyroid problems, kidney issues, or gut sensitivities, they can have serious side effects," he said. 'Also, many people stop the medicine suddenly if they feel sick, which can mess up their metabolism and lead to quick weight regain or unstable blood sugar levels." Eli Lilly India Acknowledges Misuse Concerns, Urges Caution Pharmaceutical giant Eli Lilly, which markets Mounjaro, has acknowledged the misuse concerns and emphasised the importance of medical oversight. 'Patient safety is Lilly's top priority. Mounjaro (tirzepatide) is approved for weight management in adults with obesity – it is not for cosmetic weight loss and Lilly neither promotes nor endorses the off-label use of tirzepatide for any individual," said an Eli Lilly India spokesperson in response to queries from News18. 'Patients should only use tirzepatide when prescribed by a licensed healthcare professional and prescriptions should be fulfilled and supplied only by registered pharmacies and providers. Any tirzepatide offered without a prescription or for purchase on the black market is unlawful. These products are either fake or being 'resold' by an individual who obtained them through illicit means. Both practices put patients at risk." The company further noted that it is working with regulators, law enforcement agencies, and online platforms globally to address the proliferation of counterfeit and unregulated versions of tirzepatide. 'Lilly has taken steps to help address the risks posed by the proliferation of counterfeit, fake, and unsafe products across the world. We encourage patients to consult their doctor or other healthcare professional regarding any side effects they may be experiencing and to ensure that they are getting genuine Lilly medicine." Don't Self-Prescribe. Visit Doctors to Choose the Best For You Dr Tarun Mittal, vice-chairperson and robotic bariatric surgeon at New Delhi-based Sir Ganga Ram Hospital, told News18 that while the drug mimics gut hormones to control appetite and blood sugar levels, it is not a one-size-fits-all solution. 'Tirzepatide (Mounjaro) is a weekly injection, and it mimics gut hormones to control appetite and blood sugar. Some people have reduced around 15-20 per cent of their total body weight using this drug," he said. However, he added that the medicine may not be effective for patients with morbid obesity, particularly those with a BMI above 50, trying to lose 40–50 kg. 'It's great for managing type 2 diabetes, but weight often comes back if you stop using it," he explained. 'Prolonged use can cause gastrointestinal issues such as severe nausea, diarrhoea, vomiting, and constipation. It slows down the emptying of the stomach, increasing the chances of reflux. It can also lead to pancreatitis, gallstones, gastroparesis, and eye-related issues. Therefore, it's not a magic pill but a serious treatment that should be followed under the strict supervision of a weight loss or bariatric surgeon. Avoid self-medication." top videos View all According to Dr Mittal, almost 10–15 per cent of the patients seen in their OPD are already using Mounjaro or other GLP-1 analogues without medical advice. He emphasised that bariatric surgery remains a safe and effective option for those with significant obesity. 'Bariatric surgery is a one-time procedure which offers, on average, 60–80 per cent of excess weight loss. It is a safe procedure that can help reverse type 2 diabetes, PCOS, sleep apnea, and more," he said. About the Author Himani Chandna Himani Chandna, Associate Editor at CNN News18, specialises in healthcare and pharmaceuticals. With firsthand insights into India's COVID-19 battle, she brings a seasoned perspective. She is particularly More Get breaking news, in-depth analysis, and expert perspectives on everything from politics to crime and society. Stay informed with the latest India news only on News18. Download the News18 App to stay updated! view comments Location : New Delhi, India, India First Published: August 07, 2025, 14:58 IST News india Doctors Flag Dangerous Trend As Mounjaro, Wegovy Misuse Spikes Among Indians For Quick Weight Loss Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Time of India
9 hours ago
- Time of India
Kelley Mack dies of a ‘rare' brain cancer; The early signs ‘The Walking Dead' actress overlooked (and what you should watch out for)
Kelley Mack, beloved for her role as Addy in The Walking Dead, tragically passed away on August 2, in Cincinnati, Ohio, at just 33 years old. Her family shared that she died peacefully, surrounded by loved ones, leaving behind a legacy of kindness, creativity, and courage. Kelley died after a quiet and brave battle with a rare form of brain cancer. In September 2024, she publicly shared her diagnosis of central nervous system glioma, a rare and aggressive brain cancer. This cancer arises in the brain or spinal cord and is known for rapid progression and difficult treatment. She underwent aggressive treatment in hopes of beating the disease. Despite her fight, she passed away peacefully on August 2, surrounded by family, her mother Kristen and aunt Karen by her side during her final moments in Cincinnati. What is the disease she was suffering from? Kelley's death was due to diffuse midline glioma (DMG), an exceptionally rare and aggressive tumor affecting the brain and spinal cord. Classified as a grade IV astrocytoma, DMG is known for its speed and severity, giving patients a poor prognosis even with treatment. Statistically, only about 10% of individuals with DMG survive beyond two years. The Walking Dead actress faced this staggering challenge head-on, a testament to her resilience. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Remember Him? Take A Deep Breath Before You See Him Now Reportingly Undo What is diffuse midline glioma (DMG)? Diffuse midline glioma (DMG) is a rare, aggressive type of cancerous brain tumor, most commonly found in children, that originates in the midline structures of the central nervous system. These tumors are characterized by their diffuse, infiltrative growth pattern and poor prognosis, with limited treatment options. DMG tumors are found in the midline structures of the brain, including the thalamus, brainstem (pons), and spinal cord. They are gliomas, meaning they arise from glial cells, which are support cells in the brain. DMGs are characterized by their diffuse, infiltrative growth, meaning they spread and invade surrounding healthy brain tissue. They are highly aggressive tumors with a poor prognosis, meaning they tend to grow rapidly and are difficult to treat effectively. DMGs are not very common. While they can occur in adults, they are most frequently diagnosed in children between the ages of 5 and 10. Due to their aggressive nature and limited treatment options, DMGs have a poor prognosis. Traditional treatments like radiation therapy and chemotherapy can offer some symptom relief, but are often ineffective in controlling tumor growth. Due to the tumor's location in delicate brain structures, according to the Brain Tumour Charity, surgical removal is often not possible. Early signs to watch out for Kelley's sudden death has shocked many, not just because of her young age, but because of how subtle and easily overlooked her early symptoms were. In late 2024, Kelley started feeling persistent lower back pain, a symptom she initially dismissed as a slipped disc. Over time, she also experienced nerve pain, shooting sensations in her legs, and unbearable discomfort when lying down. These early warnings (back pain, leg pain, nerve issues) can be easy to miss or attributed to a fast lifestyle, stress, and a lack of rest. Many people chalk them up to everyday strains. But in some cases, they're red flags: signs that something more serious may be happening deeper within the spine or brain. An emergency MRI later revealed an abnormal mass on her spinal cord, leading to the diagnosis of diffuse midline glioma. Kelley's sudden death left the fans mourning, but with several lessons, especially on how not to overlook the common signs and mistake them for simple inconveniences. If you're experiencing persistent back or nerve pain, especially if paired with leg numbness or shooting sensations, it shouldn't be ignored. If pain becomes worsening or constant, particularly when lying down, it's critical not to dismiss it as strain or posture-related. Getting a doctor's evaluation and imaging, like an MRI, can reveal serious issues that would otherwise remain hidden. Even common symptoms can mask dangerous conditions. Her story highlights an important truth: it's always better to check, even if you're young and feel otherwise healthy. Who was Kelley Mack? Born Kelley Klebenow on July 10, 1992, she grew up in Cincinnati with a deep love for filmmaking fueled by a childhood video camera. After graduating from Hinsdale Central High School in 2010, she earned a cinematography degree from Chapman University in 2014. Over her career, she accumulated 35 acting roles and five producer credits, proving her creative versatility. Her breakthrough role came in Season 9 of The Walking Dead (2018–2019) as Addy, a resident of the Hilltop Colony. Though her time on the show was brief, her performance was memorable and showed her ability to bring depth to ensemble casts. Kelley's talents extended beyond the zombie world. She portrayed Penelope Jacobs in Season 8 of Chicago Med and appeared in 9‑1‑1. Her film roles include Alice in the psychological thriller Broadcast Signal Intrusion (2021) and Wilda in Delicate Arch (2024). Her final on-screen project was the comedy-drama Universal, released just weeks before her passing, where she was both in a starring role and as an executive producer alongside Joe Thomas.
Economic Times
15 hours ago
- Economic Times
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Synopsis Novo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sales growth, especially in the U.S. The Danish drugmaker, which lost $95 billion in market value after cutting full-year forecasts, said over one million Americans still use compounded GLP-1 drugs despite a U.S. ban. Reuters Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly, the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
